API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com/news-release/2024/07/25/2918519/0/en/Verona-Pharma-to-Report-Second-Quarter-2024-Financial-Results-and-Provide-Corporate-Update.html
https://www.fiercepharma.com/pharma/icer-says-veronas-price-copd-treatment-ohtuvayre-will-restrict-access
https://www.globenewswire.com/news-release/2024/06/26/2904839/0/en/Verona-Pharma-Announces-US-FDA-Approval-of-Ohtuvayre-ensifentrine.html
https://www.fiercepharma.com/pharma/veronas-ensifentrine-will-be-paradigm-shift-copd-treatment-globaldata-says
https://www.veronapharma.com/media/verona-pharma-announces-650-million-strategic-financing-oaktree
https://www.globenewswire.com/news-release/2024/05/09/2878633/0/en/Verona-Pharma-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com//news-release/2023/10/06/2755894/0/en/Verona-Pharma-to-Host-Investor-Update-on-Commercialization-Preparation-for-Ensifentrine-on-October-18-2023.html
https://www.globenewswire.com//news-release/2023/09/11/2740487/0/en/Verona-Pharma-Announces-the-US-FDA-has-Accepted-the-New-Drug-Application-Filing-for-Ensifentrine-for-the-Maintenance-Treatment-of-COPD.html
https://pharmafile.com/news/verona-pharma-submits-fda-new-drug-application-for-copd-treatment/
https://endpts.com/verona-says-second-phiii-for-copd-drug-hits-the-mark-plans-2023-nda-filing/
https://www.globenewswire.com/news-release/2022/12/20/2576784/0/en/Verona-Pharma-Announces-Ensifentrine-Meets-Primary-and-Key-Secondary-Endpoints-in-Phase-3-ENHANCE-1-Trial-for-COPD.html
https://www.globenewswire.com/news-release/2022/10/14/2534398/0/en/Verona-Pharma-Announces-Analyses-Demonstrating-Ensifentrine-Reduced-Exacerbation-Rates-Across-Subgroups-in-Phase-3-ENHANCE-2-Trial-for-COPD.html
https://www.prnewswire.com/news-releases/nuance-pharma-announces-clearance-of-ind-application-for-ensifentrine-pivotal-clinical-trials-for-copd-in-china-301609010.html
https://www.trialsitenews.com/a/verona-pharma-reports-results-from-phase-3-enhance-2-trial-supporting-use-of-nebulized-ensifentrine-for-maintenance-of-copd-0d499cd1
https://www.globenewswire.com/news-release/2022/08/08/2494355/0/en/Verona-Pharma-to-Announce-Top-line-Data-from-Phase-3-ENHANCE-2-Trial-of-Nebulized-Ensifentrine-for-COPD.html
https://www.globenewswire.com/news-release/2022/06/09/2459311/0/en/Verona-Pharma-Completes-Enrollment-in-Phase-3-ENHANCE-1-Trial-Evaluating-Ensifentrine-for-Maintenance-Treatment-of-COPD.html
https://www.biospectrumasia.com/news/95/18344/uk-pharma-firm-invests-219m-to-scale-up-respiratory-drug-in-china-taiwan-hk-macau.html
https://www.prnewswire.com/news-releases/verona-pharma-and-nuance-pharma-announce-219-million-strategic-collaboration-to-develop-and-commercialize-ensifentrine-in-greater-china-301309693.html
http://www.pharmatimes.com/news/verona_pharma_launches_late-stage_copd_trial_programme_1351157
https://www.globenewswire.com/news-release/2020/09/23/2097745/0/en/Verona-Pharma-Initiates-Phase-3-Clinical-Trials-with-Nebulized-Ensifentrine-for-the-Maintenance-Treatment-of-COPD.html
https://www.pharmaceutical-technology.com/features/verona-covid19-copd/
https://www.veronapharma.com/media/verona-pharma-announces-publication-phase-2b-copd-symptom-data
https://pharmaphorum.com/news/verona-to-test-copd-hopeful-ensifentrine-in-covid-19-patients/
http://www.pharmatimes.com/news/inhaled_ensifentrine_will_be_assessed_in_hospitalised_patients_1348967
http://www.pharmatimes.com/news/priority_review_for_imfinzis_less-frequent_dosing_regimen_1347020
https://www.globenewswire.com/news-release/2020/05/14/2033213/0/en/Verona-Pharma-Announces-FDA-Response-to-End-of-Phase-2-Briefing-Package-for-Ensifentrine-in-COPD-and-Outlines-Phase-3-ENHANCE-Clinical-Program.html
https://www.veronapharma.com/media/verona-pharma-reports-positive-efficacy-and-safety-data-single
http://www.pharmatimes.com/news/ensifentrine_improves_lung_function_in_copd_patients_1332703
http://www.pharmatimes.com/news/verona_unveils_phase_ii_copd_results_1325711
https://www.veronapharma.com/media/verona-pharma-reports-positive-top-line-data-4-week-phase-2b
https://www.nasdaq.com/articles/verona-pharma-vrna-jumps-45-on-looming-trial-data-2019-12-27
https://www.biospace.com/article/releases/verona-pharma-completes-enrollment-in-phase-2b-clinical-trial-with-nebulized-ensifentrine-in-moderate-to-severe-copdresults-to-inform-development-plan-and-dose-selection-for-phase-3/?s=95
http://www.pharmatimes.com/news/verona_pharma_share_positive_ensifentrine_results_in_copd_1296438
http://www.pharmatimes.com/news/another_eu_patent_for_verona_in_copd_drug_1284071
https://globenewswire.com/news-release/2019/01/09/1682728/0/en/Verona-Pharma-Receives-WHO-Approval-for-ensifentrine-as-Recommended-INN-for-RPL554.html
https://drug-dev.com/verona-pharma-completes-enrollment-in-phase-2-clinical-trial/
http://www.pharmatimes.com/news/veronas_rpl554_improves_lung_function_in_cf_trial_1225272
https://www.fiercebiotech.com/biotech/verona-jumps-as-midphase-cystic-fibrosis-data-dial-up-hopes
http://www.pharmatimes.com/news/verona_pharma_begins_dosing_rpl554_in_phase_iib_copd_trial_1199301